AbbVie
Aldeyra Therapeutics and AbbVie enter agreement for development and commercialisation of reproxalap
November 2, 2023Business Services AbbVie, Aldeyra Therapeutics, Opthalmology, reproxalap
Aldeyra Therapeutics and AbbVie have announced that they have entered into an exclusive option agreement for the license to develop, …
AbbVie’s Aquipta receives MHRA marketing authorisation
September 5, 2023Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines
AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …
AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa
July 25, 2023Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib
AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …
Abu Dhabi’s Department of Health, M42 and AbbVie enter strategic partnership
June 20, 2023Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership
Abu Dhabi’s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research …
Abbvie psoriatic arthritis drug approved for use in Scotland
May 11, 2021Manufacturing and Production AbbVie, NHS, arthritis, psoriatic arthritis
Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in …
AbbVie funds Mitokinin’s Parkinson’s research with option to buy
March 3, 2021Research and Development AbbVie, Mitokinin, Parkinson's
AbbVie has landed an option to buy neurodegenerative disease-focused biotech Mitokinin following completion of investigational new drug (IND)-enabling studies on …
AbbVie’s rheumatoid arthritis drug Rinvoq approved for NHS Scotland
February 9, 2021Manufacturing and Production AbbVie, rheumatoid arthritis
The Scottish Medicines Consortium (SMC) has recommended AbbVie’s rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for use on the NHS in …
AbbVie’s psoriatic arthritis and ankylosing spondylitis drug gets EU approval
January 26, 2021Manufacturing and Production AbbVie
The European Commission (EC) has approved AbbVie’s RINVOQTM (upadacitinib 15 mg), an oral, once-daily selective and reversible JAK inhibitor for …
AbbVie buys COVID-19 antibody licence from Harbour BioMed
December 16, 2020Research and Development AbbVie, COVID-19, Harbour BioMed, antibody
Harbour BioMed (HBM) and Utrecht University (UU) have announced that their fully human, SARS-CoV-2 neutralising antibody 47D11 and programme, has …
AbbVie unveils new Phase 3 upadacitinib data in moderate to severe ulcerative colitis
December 10, 2020Research and Development AbbVie, upadacitinib
AbbVie has announced data from the first of two Phase 3 studies investigating the efficacy of upadacitinib in treating moderate …
NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia
November 10, 2020Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax
NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …
FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal
October 19, 2020Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma
The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …
AbbVie’s Rinvoq smashes Phase 3 efficacy targets in atopic dermatits
July 22, 2020Research and Development AbbVie, atopic dermatits, pharma, upadacitinib
AbbVie has lifted the curtain on data from the second Phase 3 trial investigating the efficacy of Rinvoq (upadacitinib) monotherapy …
FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns
June 29, 2020Sales and Marketing AbbVie, Allergan, FDA, pharma
The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, Abicipar pegol, as treatment for …
AbbVie’s Venclexta plus azacitidine shows improved survival and remissions rates in leukaemia patients
June 15, 2020Sales and Marketing AbbVie, leukaemia
AbbVie have announced positive results from its latest Phase 3 clinical trial where Venclexta plus azacitidine improved survival and remission …
Latest content
FibroFind appoints Lee Borthwick as CEO
